Additional Data Show Survival Benefit in Both Pre-Treated (Surgery, Radiation, Chemotherapy) as well as Previously Untreated Patients Overall Survival Was Significantly Longer in Patients Less Than or Equal to 60 years of Age, Increasing From a Median of 3.1 to 10.9 Months
Ongoing Analyses Of Randomized Phase 2/3 ATC Data, Including Subgroup Analyses, Continue To Show ZYBRESTAT(TM) (CA4P) Improves Overall Survival In Patients With Anaplastic Thyroid Cancer (ATC)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.